Hani Gabra
Founder bei Papyrus Therapeutics, Inc.
Profil
Hani Gabra is the founder of Papyrus Therapeutics, Inc. He is currently a Professor at Imperial College London.
He previously worked as the Director of Clinical Development at BerGenBio ASA from 2021 to 2022 and as the Vice President of Early Clinical Development at AstraZeneca PLC.
Aktive Positionen von Hani Gabra
| Unternehmen | Position | Beginn |
|---|---|---|
| Imperial College London | Corporate Officer/Principal | - |
Papyrus Therapeutics, Inc.
 Papyrus Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Papyrus Therapeutics, Inc. is a preclinical stage biopharma American company that focuses on developing cancer therapeutics based on a novel target, opioid-binding cell adhesion molecule (OPCML). Papyrus Therapeutics is based in Oxford, UK. The company's expertise in this target is based on years of research and multiple publications by the company's co-founder and chief scientific adviser, Professor Hani Gabra. The company was founded by Paul Blake and Hani Gabra, and Paul Blake has been the CEO since incorporation. | Founder | - |
Ehemalige bekannte Positionen von Hani Gabra
| Unternehmen | Position | Ende |
|---|---|---|
| BERGENBIO ASA | Chief Tech/Sci/R&D Officer | - |
| ASTRAZENECA PLC | Corporate Officer/Principal | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| ASTRAZENECA PLC | Health Technology |
| BERGENBIO ASA | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Papyrus Therapeutics, Inc.
Papyrus Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Papyrus Therapeutics, Inc. is a preclinical stage biopharma American company that focuses on developing cancer therapeutics based on a novel target, opioid-binding cell adhesion molecule (OPCML). Papyrus Therapeutics is based in Oxford, UK. The company's expertise in this target is based on years of research and multiple publications by the company's co-founder and chief scientific adviser, Professor Hani Gabra. The company was founded by Paul Blake and Hani Gabra, and Paul Blake has been the CEO since incorporation. | Commercial Services |
